Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs DYN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DYN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–2 Matrix Metrics)

DYN Overall Winner 6-Pillar Tally: ZBIO 0 – 5 DYN (1 Tie) Matrix Metrics: ZBIO 2 – 5 DYN

As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas DYN carries 47.5/100 (HOLD) at $16.70 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. DYN 47.5/100 HOLD), DYN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2747.5% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile DYN is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs DYN
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
DYN NASDAQ Head-to-Head Winner
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$16.70
-2.68% 1D
Market Cap $3.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.71β · 58% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -17.2%) with fading momentum, RSI 46
RSI-14: 45.9 · SMA20: $17.09 · SMA50: $16.81

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 0 – 5 DYN)

Columns: Metric · ZBIO · DYN
1. Valuation Multiples DYN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M 0.19x
EV / Revenue N/M N/M
2. Growth & Scale DYN
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $1.9B $3.2B
3. Profitability & Quality DYN
Gross Margin N/A N/A
Operating Margin -2747.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -265.1% -74.6%
4. Balance Sheet & Cash Flow DYN
Cash Generation (TTM) -$273M -$569M
Cash Flow Margin N/A N/A
Net Cash / Leverage $177M Net Cash $694M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DYN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 95.3% (12th %ile) 125.1% (25th %ile)
Put/Call OI Skew N/A 0.10x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (2) vs DYN (5)
Institutional Metric ZBIO DYN Criterion Row Edge
Market Capitalization
Scale
$1.9B $3.2B Larger Scale DYN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth DYN
Operating Margin (TTM)
Profitability
-2747.5% 0.0% Higher Margin DYN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-265.1% -74.6% Higher ROE DYN
52-Week Range Position
Momentum
46% ($14–$45) 20% ($14–$27) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 1.71β · 58% Vol Lower Realized Risk DYN
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.19x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) -$569M ($694M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DYN +4.75 pp
ZBIO: +12.44% · DYN: +17.19%
3M Horizon ZBIO +23.3 pp
ZBIO: -12.47% · DYN: -35.77%
6M Horizon ZBIO +64.2 pp
ZBIO: +65.17% · DYN: +0.97%
1Y Horizon DYN +10.37 pp
ZBIO: -21.68% · DYN: -11.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs DYN. Trailing 12-month operating profitability (ZBIO -2747.5% vs DYN 0.0%) and valuation multiples (ZBIO N/M vs DYN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M
DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 95.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DYN BREAKDOWN
68d in phase · OBV ACCUMULATION
Current IV 125.1%
IV Percentile 25th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZBIO vs DYN Key Questions & Quantitative Answers

As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas DYN carries 47.5/100 (HOLD) at $16.70 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. DYN 47.5/100 HOLD), DYN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2747.5% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile DYN is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DYN leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with DYN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus N/A for DYN. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DYN.

DYN screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus DYN (-74.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, DYN carries 125.1% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.